Cutting communication between normal and tumour cells in pancreatic cancer
Co-funded with:
Pancreatic Cancer Research Fund
Cancer types:
Pancreatic cancer
Project period:
–
Research institute:
Queen Mary University of London
Award amount:
£224,010
Location:
United Kingdom
Dr Angus Cameron and his team aim to find out how normal cells in pancreatic tumours are recruited by cancer cells to support the growth and progression of the disease. Better understanding these processes might help to identify new drug targets in the future.
Meet the scientist
Angus Cameron is a senior lecturer in tumour biology at Barts Cancer Institute in London. His lab focuses on proteins called "kinases" and how they help cancer cells to grow and move about. Angus is a keen runner and ran the London Marathon in memory of his friend Nick who sadly passed away from cancer, raising over £5000 for brain cancer research.
The science
Tumours aren't just masses of cancer cells but also contain lots of normal cells that have been recruited by the tumour to help it grow. One of these cells is known as a cancer-associated fibroblast (CAF) and evidence shows that they play a critical role in the progression of cancer. They have a strong presence in pancreatic cancer and Dr Cameron's team have recently identified a new protein, which is required for CAFs to assist the growth of a tumour. The team have developed a genetically engineered mouse which they now want to use to study exactly how this protein allows CAFs to communicate with tumour cells and whether there is an effective way to block this communication so that tumour growth can be prevented. This will not only give a better understanding of the biology of pancreatic cancer but could also identify a new drug target for treating one of the deadliest cancers.